{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:09:04Z","timestamp":1788307744814,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["97-03-160-39686"],"award-info":[{"award-number":["97-03-160-39686"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["92-01-160-21598"],"award-info":[{"award-number":["92-01-160-21598"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.068","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T08:26:58Z","timestamp":1556526418000},"page":"3221-3228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB\/c mice"],"prefix":"10.1016","volume":"37","author":[{"given":"Samira","family":"Elikaee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mohebali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sassan","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Eshraghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.068_b0005","unstructured":"World Health Organization. Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region; 2014."},{"key":"10.1016\/j.vaccine.2019.04.068_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.actatropica.2016.11.004","article-title":"Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013","volume":"166","author":"Holakouie-Naieni","year":"2017","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.04.068_b0015","first-page":"348","article-title":"Visceral leishmaniasis in Iran: review of the epidemiological and clinical features","volume":"8","author":"Mohebali","year":"2013","journal-title":"Iran J Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the treatment and control of leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2016.00151","article-title":"Cutaneous leishmaniasis vaccination: a matter of quality","volume":"7","author":"De Luca","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0030","doi-asserted-by":"crossref","first-page":"631460","DOI":"10.1155\/2012\/631460","article-title":"Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites","volume":"2012","author":"Selvapandiyan","year":"2012","journal-title":"J Trop Med"},{"key":"10.1016\/j.vaccine.2019.04.068_b0035","doi-asserted-by":"crossref","first-page":"13951","DOI":"10.1073\/pnas.0905184106","article-title":"Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process","volume":"106","author":"Okwor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.068_b0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.det.2010.08.014","article-title":"Innate immunity and Leishmania vaccination strategies","volume":"29","author":"Birnbaum","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.vaccine.2019.04.068_b0045","first-page":"455","article-title":"Genetically modified live attenuated parasites as vaccines for leishmaniasis","volume":"123","author":"Selvapandiyan","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2019.04.068_b0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00005-008-0010-9","article-title":"Live attenuated Leishmania vaccines: a potential strategic alternative","volume":"56","author":"Silvestre","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.vaccine.2019.04.068_b0055","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.068_b0060","doi-asserted-by":"crossref","first-page":"e0004963","DOI":"10.1371\/journal.pntd.0004963","article-title":"Live attenuated Leishmania donovani Centrin knock out parasites generate non-inferior protective immune response in aged mice against Visceral Leishmaniasis","volume":"10","author":"Bhattacharya","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.068_b0065","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.vaccine.2013.01.048","article-title":"Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs","volume":"31","author":"Fiuza","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.068_b0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.04.068_b0075","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.4049\/jimmunol.172.6.3793","article-title":"Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response","volume":"172","author":"Uzonna","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1590\/S0074-02761999000400011","article-title":"A dhfr-ts-Leishmania major knockout mutant cross-protects against Leishmania amazonensis","volume":"94","author":"Veras","year":"1999","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2019.04.068_b0085","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.1202801","article-title":"Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB\/c mice","volume":"190","author":"Dey","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0090","first-page":"24","article-title":"Development of a new live attenuated Leishmania major p27 gene knockout: Safety and immunogenicity evaluation in BALB\/c mice","volume":"332","author":"Elikaee","year":"2018","journal-title":"CellImmunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exppara.2006.07.002","article-title":"Leishmania major: immune response in BALB\/c mice immunized with stress-inducible protein 1 encapsulated in liposomes","volume":"115","author":"Badiee","year":"2007","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-3024.1985.tb00098.x","article-title":"A limiting dilution assay for quantifying Leishmania major in tissues of infected mice","volume":"7","author":"Titus","year":"1985","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0105","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1016\/j.vaccine.2014.05.009","article-title":"Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis","volume":"32","author":"Selvapandiyan","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.068_b0110","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.vaccine.2014.11.039","article-title":"Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum","volume":"33","author":"Fiuza","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.068_b0115","first-page":"892817","article-title":"Development of vaccines against visceral leishmaniasis","volume":"2012","author":"Evans","year":"2011","journal-title":"J Trop Med"},{"key":"10.1016\/j.vaccine.2019.04.068_b0120","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.0105-2896.2004.00190.x","article-title":"Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?","volume":"201","author":"McMahon-Pratt","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2019.04.068_b0125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1074-7613(00)80342-8","article-title":"IL-4 rapidly produced by V\u03b24 V\u03b18 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB\/c mice","volume":"6","author":"Launois","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.04.068_b0130","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.4049\/jimmunol.162.10.6132","article-title":"IL-4-and IL-4 receptor-deficient BALB\/c mice reveal differences in susceptibility to Leishmania major parasite substrains","volume":"162","author":"Noben-Trauth","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0135","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1128\/IAI.71.8.4804-4807.2003","article-title":"Both interleukin-4 (IL-4) and IL-4 receptor \u03b1 signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity","volume":"71","author":"St\u00e4ger","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.04.068_b0140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fimmu.2013.00156","article-title":"Interferon gamma in leishmaniasis","volume":"4","author":"Kima","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0145","doi-asserted-by":"crossref","first-page":"e0004322","DOI":"10.1371\/journal.pntd.0004322","article-title":"Intradermal immunization of Leishmania donovani centrin knock-out parasites in combination with salivary protein LJM19 from sand fly vector induces a durable protective immune response in hamsters","volume":"10","author":"Fiuza","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.068_b0150","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.1303145","article-title":"Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana","volume":"193","author":"Dey","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0155","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3389\/fimmu.2018.01176","article-title":"Centrin-Deleted Leishmania donovani Parasites Help CD4+ T Cells to Acquire Th1 Phenotype and Multi-Functionality Through Downregulation of CD200\u2013CD200R Immune Inhibitory Axis","volume":"9","author":"Singh","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0160","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4049\/jimmunol.0900276","article-title":"Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis","volume":"183","author":"Selvapandiyan","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0165","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1038\/s41598-018-30076-7","article-title":"Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice","volume":"8","author":"Santi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.04.068_b0170","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fimmu.2017.00100","article-title":"A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani nucleoside hydrolase (NH36) optimizes cross-protection against Leishmania amazonesis infection","volume":"8","author":"Alves-Silva","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0175","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1038\/srep10706","article-title":"Genetically engineered ascorbic acid-deficient live mutants of Leishmania donovani induce long lasting protective immunity against visceral leishmaniasis","volume":"5","author":"Anand","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.04.068_b0180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1756-3305-4-150","article-title":"Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation","volume":"4","author":"Carri\u00f3n","year":"2011","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2019.04.068_b0185","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4269\/ajtmh.2007.76.579","article-title":"Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB\/c mice","volume":"76","author":"Tonui","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.04.068_b0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/expr.1996.4117","article-title":"Heterologous Protection by Leishmania donovani for Leishmania major Infections in the Vervet Monkey Model of the Disease","volume":"85","author":"Gicheru","year":"1997","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.068_b0195","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.vaccine.2012.11.065","article-title":"Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis","volume":"31","author":"McCall","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.068_b0200","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00436-012-2899-5","article-title":"Previous exposure to a low infectious dose of Leishmania major exacerbates infection with Leishmania infantum in the susceptible BALB\/c mouse","volume":"111","author":"Nation","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2019.04.068_b0205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"Peacock","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.vaccine.2019.04.068_b0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2164-9-255","article-title":"Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species","volume":"9","author":"Rochette","year":"2008","journal-title":"BMC Genomics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:14:53Z","timestamp":1777536893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":42,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305560"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}